MedTrace Logo

A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis

NCT04503746 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2022-08-11

No results posted yet for this study

Summary

The main objective of this study is to evaluate efficacy and safety of ALH-L1005 in patients with chronic periodontitis

Conditions

  • Chronic Periodontitis

Interventions

DRUG

ALH-L1005 600mg/day

ALH-L1005 300mg 2 tablet and placebo 2 tablet

DRUG

ALH-L1005 1,200mg/day

ALH-L1005 300mg 4 tablet

DRUG

Placebo

Placebo 4 tablet

Sponsors & Collaborators

  • AngioLab, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2021-12-13
Completion
2021-12-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04503746 on ClinicalTrials.gov